O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate

Acute Toxicity: inhalation

Administrative data

Endpoint:

acute toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

key study

Study period:

11 October 2004 to 2 November 2004

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2004

Report date:

2004

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 403 (Acute Inhalation Toxicity)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1300 (Acute inhalation toxicity)

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EU Method B.2 (Acute Toxicity (Inhalation))

Deviations:

no

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate

EC Number:

255-255-2

EC Name:

O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate

Cas Number:

41198-08-7

Molecular formula:

C11H15BrClO3PS

IUPAC Name:

4-bromo-2-chlorophenyl ethyl (propylsulfanyl)phosphonate

Test material form:

liquid

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Administration / exposure

Route of administration:

inhalation: aerosol

Type of inhalation exposure:

nose only

Vehicle:

other: none

Analytical verification of test atmosphere concentrations:

yes

Remarks:

2.2 mg/L

Duration of exposure:

ca. 4 h

Concentrations:

2 mg/L

No. of animals per sex per dose:

5 animals/sex/gp

Control animals:

no

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LC50

Effect level:

> 2.2 mg/L air (analytical)

Based on:

other: no deaths observed

Exp. duration:

4 h

Any other information on results incl. tables

Mortality:

No deaths were observed.

 

Clinical observations:

During exposure clinical observations were associated with restraint, including wet fur and salivation. In addition all animals had increased breathing rate.

 

Post exposure hunched posture and piloerection were observed in one female.

 

Changes indicative of irritation of the respiratory tract (increased breathing rate and abnormal respiratory noise in some animals) were observed post exposure.

 

By day 3, post exposure, the clinical condition of the animals had greatly improved, with all animals fully recovered by day 7 of the study.

 

Bodyweight:

Three males and 1 female had gained weight by day 8 of the study. All males and 2 females had gained weight by the end of the study. The remaining females showed some evidence of weight gain during the study.

 

Necropsy:

There were no test material related changes observed.

 

Table 7.2.2-1: Particulate concentration

Target particulate concentration (mg/L)	Measured particulate concentration (mg/L) Mean ± SD
2	2.20±0.25

 

Table 7.2.2-2: Aerodynamic particle size distribution

Time into exposure (minutes)	Median size (MMAD) (um)	GSD
62	3.51	1.65
180	3.01	1.59

Applicant's summary and conclusion

Conclusions:

Nose only exposure to a particulate concentration of 2.2 mg Profenofos Technical (CGA15324)/L resulted in no deaths and no adverse effects. It is concluded that the LD50 of Profenofos Technical (CGA15324) exceeds 2.2 mg/L.

Executive summary:

A group of 5 male and 5 female SD rats were exposed nose only for a single 4 hour period to Profenofos Technical (CGA15324) at a target particulate concentration of 2 mg/L. Test atmospheres were analysed for particulate concentration and Profenofos Technical (CGA15324). The particle size distribution of the test atmosphere was analysed twice during the exposure period. Following exposure, the animals were retained without treatment for 14 days. Clinical observations and bodyweights were recorded throughout the study and at the end of the scheduled period, the animals were killed and subjected to a gross examination post mortem.

 

The achieved test atmospheres had the following characteristics: Achieved concentration: 2.2 mg/L, MMAD 3.51 and 3.01 um, GSD 1.675 and 1.59.

 

There were no deaths. Transient signs of respiratory irritation were seen in all animals. There were no test material related macroscopic findings observed at necropsy.

 

Nose only exposure to a particulate concentration of 2.2 mg Profenofos Technical (CGA15324)/L resulted in no deaths and no adverse effects. It is concluded that the LD₅₀ of Profenofos Technical (CGA15324) exceeds 2.2 mg/L.